Agenus | AGEN - Current Assets


Agenus reported $78.81M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Agenus USD 78.81M 16.47M Jun/2026
Amgen USD 34.36B 598M Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Celldex Therapeutics USD 663.74M 61.2M Sep/2026
CSL USD 11.85B 1000K Dec/2025
Eli Lilly USD 65.26B 591M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Glaxosmithkline GBP 17.9B 134M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Intrexon USD 23.72M 45.04M Jun/2024
J&J USD 56.35B 3.42B Sep/2026
Jiangsu Hengrui CNY 54.55B 4.95B Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merck EUR 13.77B 393M Jun/2026
Merck USD 38.94B 2.26B Sep/2026
Northwest Biotherapeutics USD 6.2M 996K Mar/2026
Novartis USD 28.75B 1.4B Sep/2026
Novavax USD 707.96M 63.14M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Veracyte USD 467.88M 106.9M Sep/2026